Navigation Links
Proteolix Presents Positive Clinical Data for Carfilzomib in Multiple Myeloma at the 2009 ASCO Annual Meeting
Date:6/1/2009

yeloma" (Abstract #8504).

"We are excited by the positive demonstration of patient benefit achieved in our trials of carfilzomib. In particular, the response rates and duration of response among heavily pre-treated patients who lack treatment alternatives are highly encouraging," said Michael Kauffman, M.D., Ph.D., Chief Medical Officer of Proteolix. "Based on the consistent efficacy and safety profile achieved from our preclinical and clinical studies of carfilzomib, we are focused on advancing this promising novel agent through late-stage evaluation, with an eye toward an accelerated approval."

Trial Expanded for Accelerated Approval Strategy

Based on the positive data achieved in this Phase 2 trial, Proteolix has expanded the Phase 2 study to enroll an additional 250 relapsed and refractory multiple myeloma patients. If positive, results from this study could form the basis for a New Drug Application (NDA) filing for accelerated approval with the U.S. Food and Drug Administration in 2010.

Patients initially receive 20mg/m(2) carfilzomib twice a week over a 28-day cycle, followed by doses of 27mg/m(2) for every cycle thereafter for up to twelve cycles. The primary endpoint for the Phase 2 study is overall response rate, defined as a complete response (CR) or partial response (PR). Secondary endpoints include clinical benefit response (CR, PR or minor response (MR)), duration of response, progression-free survival, time to progression, overall survival and safety. To date, more than 140 patients have been enrolled in the study. Proteolix anticipates reporting results from this accelerated approval trial in the first half of 2010.

Carfilzomib Active in Single-Agent and Combination Regimens

Proteolix also presented data from two ongoing studies of carfilzomib in multiple myeloma patients during the Lymphoma and Plasma Cell Disorders poster session.


'/>"/>

SOURCE Proteolix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting
2. Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology
3. Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma
4. Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients With Relapsed Solid Tumors
5. Proteolix Initiates Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
8. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
9. TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry
10. Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology 2009 Meeting
11. MedImmune Presents New Data Demonstrating Increased Risk for Medically Attended RSV in Late-Preterm Infants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... -- Market Research Report on Global and Chinese ... and in-depth market survey on Global and ... firstly reviews the basic information of X-Ray Crystallography ... The report then explores global and China,s top ... specification, capacity, Production value, and market share etc. ...
(Date:8/29/2014)... 29, 2014  Chuma Holdings, Inc. (OTCBB:CHUM) (the ... turnkey support services for the lawfully organized cannabis ... and approved the Company,s name and symbol change ... will be known as Chuma Holdings, Inc. ... a merger with the Company,s wholly-owned subsidiary, Chuma ...
(Date:8/29/2014)... HILL, N.C. , Aug. 29, 2014 ... Leaders (KOLs) can be the difference between a product,s ... to effectively map and stratify KOL targets – and ... build the type of strong relationships upon which successful ... research, savvy pharma companies have identified internal inconsistencies in ...
Breaking Medicine Technology:X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 2X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 3X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 5CannaMed Announces Name Change and Trading Symbol Change 2CannaMed Announces Name Change and Trading Symbol Change 3Implementing a Strategic Thought Leader Management & Engagement System 2
... , LAUSANNE, Switzerland, October 15 ... low-cost, integrated molecular and,immunodiagnostics based on its proprietary micro-technology ... equity financing round. The,Company raised EUR 10 million ( ... investors. , The deal was ...
... Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the ... http://www.cordblood-america.com ) focused on bringing the life ... for families nationwide and internationally, today addressed shareholder questions ... interview of Matthew Schissler, founder and CEO, by analyst ...
Cached Medicine Technology:Biocartis Raises EUR10 Million in Series A Financing Round 2Biocartis Raises EUR10 Million in Series A Financing Round 3Cord Blood America Details Las Vegas Laboratory Progress in Analyst Interview 2Cord Blood America Details Las Vegas Laboratory Progress in Analyst Interview 3
(Date:8/30/2014)... 30, 2014 August 28th, 2014: ... in our society and the toll that takes on ... vital that continuing education for physical therapists addresses this ... physical therapists help others, Hands-On Seminars is offering discounts ... , Three learning styles are available to fit the ...
(Date:8/30/2014)... Tulsa, OK (PRWEB) August 30, 2014 LiveStreamingFitness.com, ... as well as other healthy lifestyle resources, is proud to ... affordable nationwide resources for at home fitness solutions by ABC’s ... a recent featured story on ABC’s Good Morning America, “Live ... Now, you can streamline your day by streamlining your workout…to ...
(Date:8/30/2014)... NJ (PRWEB) August 30, 2014 Ms. Meriwether’s ... her. She certainly has an impressive resume to boost. ... Miss USA in 2012. However, she’s also a two ... Grad student. Nana trained for the 2008 Olympics and ... Miss USA website, “This six-foot beauty from Potomac, Maryland is ...
(Date:8/30/2014)... Jake W., 18, is completing his high school degree ... Adventures transition program known as Beyond the Basics. ... actually start on a real career path,” said Jake. “ ... He has six months of sobriety under his belt after ... continue on to the Beyond the Basics transition program notes ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 When a prominent ... ensue, as happened on Wednesday, August 27th, when news began ... on JPMorgan Chase & Co and at least one ... is actually investigating attacks on seven prominent banks , ... may be affected, and the buzz quickly goes viral. ...
Breaking Medicine News(10 mins):Health News:Leader in Manual Therapy Continuing Education Makes it Easier for Physical Therapists to Improve Results on Patients 2Health News:LiveStreamingFitness.com is New Trend In Fitness 2Health News:NJ Top Dentists Announces Cover Model for the Healthy Living: Top Dentists Issue 2Health News:Big Name Bank Hacks Highlight the Importance of Regular Testing and Effective Emergency Response 2Health News:Big Name Bank Hacks Highlight the Importance of Regular Testing and Effective Emergency Response 3Health News:Big Name Bank Hacks Highlight the Importance of Regular Testing and Effective Emergency Response 4Health News:Big Name Bank Hacks Highlight the Importance of Regular Testing and Effective Emergency Response 5
... 4 (HealthDay News) -- Rates of head and neck cancer ... without any known risk factors. Now, a study suggests that ... of precancerous cells in the mouth. Previous research ... the lungs are exposed to smoke. This may lead to ...
... study of its kind, a research team led by Michigan ... the most traumatic situations were less likely to suffer health ... surveyed Army troops fighting in Iraq, could have implications for ... events such as death. Training these first-responders to think in ...
... (RA) who are current smokers were less likely to achieve ... inhibitors than those who never smoked. The study by researchers ... the past did not experience a lower response to these ... 2011 issue of Arthritis & Rheumatism , a journal ...
... Amanda Gardner HealthDay Reporter , MONDAY, Jan. 3 ... cancer on the left side of the colon, new research ... right side. The finding contradicts some previous research that ... However, the right-side benefit shown in the new study, published ...
... FOR MODERATE TO SEVERE ASTHMA ... is safe and effective an add-on treatment to corticosteroids for ... Uruguay, Argentina, and Chile performed a meta-analysis on eight trials ... At the end of the steroid reduction phase, patients taking ...
... The rapid growth in use of medical diagnostic imaging, ... radiation exposure in adults and the potential for future cancer ... led by University of Michigan researchers now shows that kids ... routine clinical care, and highlights the importance of initiatives to ...
Cached Medicine News:Health News:Estrogen May Play Role in Rising Rates of Head, Neck Cancer 2Health News:MSU leads first study of resiliency on the battlefield 2Health News:Current smokers with early rheumatoid arthritis less responsive to TNF inhibitors, methotrexate 2Health News:Colonoscopies May Not Have 'Blind Spot' After All 2Health News:Colonoscopies May Not Have 'Blind Spot' After All 3Health News:News briefs from the January issue of Chest 2Health News:U-M study: Kids frequently exposed to medical imaging procedures that use radiation 2Health News:U-M study: Kids frequently exposed to medical imaging procedures that use radiation 3
For the quantitative in vitro determination of Lactate Dehydrogenase (LD) in serum and plasma....
Latex agglutination slide test for the qualitative and semi-quantitative in vitro determination of Rheumatoid Factor in serum....
For the quantitative in vitro determination of IgG in serum and plasma. This product is suitable for use on the Aeroset...
Latex agglutination slide test for the qualitative and semi-quantitative in vitro determination of CRP in serum....
Medicine Products: